Zobrazeno 1 - 10
of 527
pro vyhledávání: '"Sébastien, Barbarot"'
Autor:
Judith Nicogossian, Stéphane Héas, Claire Thénié, Margaux Noel, Laurent Misery, Sébastien Barbarot, Fabienne Martin Juchat
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1325-1333 (2024)
Abstract Background A considerable number of patients with moderate to severe atopic dermatitis (AD) are undertreated and have inadequate control of their symptoms leading to a hight patient dissatisfaction during their care. The VECUDA study, was co
Externí odkaz:
https://doaj.org/article/0f198fe28ca64ed5a74d317751a91323
Autor:
Rémi Strizzolo, MD, Julien Seneschal, MD, PhD, Angèle Soria, MD, PhD, Delphine Staumont-Sallé, MD, PhD, Sébastien Barbarot, MD, PhD, Manuelle Viguier, MD, PhD, Marie Jachiet, MD, Audrey Nosbaum, MD, PhD, Aude Clément, MD, Marie Tauber, MD, PhD, Stéphanie Mallet, MD, Aurélie Du-Thanh, MD, PhD
Publikováno v:
World Allergy Organization Journal, Vol 17, Iss 7, Pp 100923- (2024)
In patients with moderate to severe atopic dermatitis (AD) showing an inadequate response to dupilumab 300mg/2weeks, few real-life studies reported the response to alternative regimen maintaining dupilumab.To assess and analyze the response to an inc
Externí odkaz:
https://doaj.org/article/904503b3e2134390a8cb3e8125589bae
Autor:
Delphine Staumont‐Sallé, Sébastien Barbarot, Jean David Bouaziz, Chan Chan, Claire Clibborn, Aurélie Du‐Thanh, Claire Feeney, Alexandre Lejeune, Laurent Misery, Audrey Nosbaum, Julien Seneschal, Angèle Soria, Fan Zhang
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 3, Pp 518-530 (2023)
Abstract Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti–interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD. Dupilumab
Externí odkaz:
https://doaj.org/article/aa94d1740f72494ab514527d99321156
Autor:
Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sébastien Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, John Nesnas
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. Objective To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment
Externí odkaz:
https://doaj.org/article/624f1c2c64ed4615b20abf91a666046c
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-9 (2021)
Abstract Background To examine the impact of executive function disorders on health-related quality of life (QoL) in children with neurofibromatosis type 1 (NF1), we conducted a prospective single-center study among 40 children with NF1 aged 8–12 y
Externí odkaz:
https://doaj.org/article/02c68f7fcf1746ba82f86a113205da51
Autor:
Lawrence F. Eichenfield, MD, Ayan Kusari, MA, Allison M. Han, MA, Sébastien Barbarot, MD, PhD, MSc, Mette Deleuran, MD, DMSc, Peter Lio, MD, Danielle Marcoux, MD, Audrey Nosbaum, MD, PhD, Jean-Francois Stalder, MD
Publikováno v:
JAAD International, Vol 3, Iss , Pp 8-13 (2021)
Background: Atopic dermatitis (AD) is a chronic, inflammatory skin disease that affects as many as 12.5% of children aged 0-17 years and 3% of the adult population. In the United States, 31.6 million children and adults are estimated to be living wit
Externí odkaz:
https://doaj.org/article/bb4b0778f4824cd3940bd5136dee9211
Autor:
Christelle Darrieutort-Laffite, Catherine Ansquer, Hélène Aubert, Françoise Kraeber-Bodéré, Agathe Masseau, Christian Agard, Mohamed Hamidou, Claire Bernier, Jean-Marie Berthelot, Benoit Le Goff, Sébastien Barbarot, Antoine Néel
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Objective To report on the characteristics and long-term course of rheumatic manifestations in Schnitzler syndrome (SchS). Methods A retrospective cohort study of patients with SchS followed between 2000 and 2020. Inclusion criteria included
Externí odkaz:
https://doaj.org/article/fabbff27aafb4999bfe695d9fd6de2a6
Autor:
Paméla Voillot, Brigitte Riche, Michel Portafax, Pierre Foulquié, Anaïs Gedik, Sébastien Barbarot, Laurent Misery, Stéphane Héas, Adel Mebarki, Nathalie Texier, Stéphane Schück
Publikováno v:
Journal of Medical Internet Research, Vol 24, Iss 1, p e31140 (2022)
BackgroundAtopic dermatitis (AD) is a chronic, pruritic, inflammatory disease that occurs most frequently in children but also affects many adults. Social media have become key tools for finding and disseminating medical information. ObjectiveThe ai
Externí odkaz:
https://doaj.org/article/139aba621eb0469b9e566c6029a3986e
Autor:
Florence Poizeau, Sébastien Barbarot, Yannick Le Corre, Emilie Brenaut, Mahtab Samimi, Hélène Aubert, Alexis Toubel, Alain Dupuy
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 12 (2021)
Numerous cases of chilblains have been observed in the course if the COVID-19 pandemic. The aims of this study were to provide comprehensive follow-up data for patients reporting chilblains, and to determine the risk factors for incomplete recovery.
Externí odkaz:
https://doaj.org/article/f8d248b4173d40c89b8209efebb97b86
Autor:
Sophie Leducq, Agnès Caille, Sébastien Barbarot, Nathalie Bénéton, Didier Bessis, Olivia Boccara, Anne-Claire Bursztejn, Christine Chiaverini, Anne Dompmartin, Catherine Droitcourt, Valérie Gissot, Dominique Goga, Laurent Guibaud, Denis Herbreteau, Anne Le Touze, Christine Léauté-Labrèze, Gérard Lorette, Stéphanie Mallet, Ludovic Martin, Juliette Mazereeuw-Hautier, Alice Phan, Patrice Plantin, Isabelle Quéré, Pierre Vabres, Hélène Bourgoin, Bruno Giraudeau, Annabel Maruani, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Background Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and
Externí odkaz:
https://doaj.org/article/c58880da25a140169bb50044eb868b2a